Evidence map›Paper›PMID 29765120›Full record

SynthesisScientific reports2018

Oncological Outcome of Primary and Secondary Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.

Peng Ge, Li Wang, Meng Lu, Lijun Mao, Wang Li, Rumin Wen, Jian Lin, Junqi Wang, Jiacun Chen

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Peng GeDepartment of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. gepengyzu@126.com.
Li WangXuzhou Medical University, Xuzhou, Jiangsu, China.
Meng LuDepartment of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Lijun MaoDepartment of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Wang LiDepartment of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Rumin WenDepartment of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Jian LinDepartment of Urology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China.
Junqi WangDepartment of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. wjq68@sina.cn.
Jiacun ChenDepartment of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. cjc7812@163.com.
Xuzhou Medical College · CNPeking University First Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conflicting results of survival outcomes for primary and secondary muscle-invasive bladder cancer (MIBC) have been reported in previous studies. Primary MIBC is defined as presentation of muscle-invasive disease at initial diagnosis while secondary MIBC presumes that non-muscle invasive disease later progressed to MIBC. Due to the varying reports, we conducted a systematic review and meta-analysis to compare survival outcomes between the two groups. Relevant studies were retrieved from Medline, Embase, the Cochrane Library, and Scopus using a comprehensive search approach. Cancer-specific survival (CSS) was the outcome measure. A total of 14 studies involving 4,075 cases were included. Patients with secondary MIBC were significantly correlated with worse CSS in model I (pooled HR: 1.29, 95% CI: 1.07-1.56, P = 0.008). The results of sensitivity analyses indicated that the omission of any single study each time did not have a significant impact on the combined risk estimates. Egger's test suggested no publication bias among these studies. The European Organization for Research and Treatment of Cancer (EORTC) risk score offers the possibility of stratifying the secondary MIBC patients into different risk groups. In high-risk NMIBC, timely radical cystectomy should be considered. Further study is required to assess the multimodal therapy in both high-risk NMIBC and secondary MIBC patients as well as to evaluate genetic and molecular drivers of tumor induction, promotion, and progression.

Indexed as

AgedDisease ProgressionFemaleHumansMaleMiddle AgedMusclesNeoplasm InvasivenessPrognosisSurvival AnalysisUrinary Bladder Neoplasms

Identifiers

PMID29765120
PMCPMC5954122
OpenAlexW2805706037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.